Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2022 | TRESR trial: Investigating an ATRi in patients with DNA damage repair loss-of-function mutant tumors

Timothy Yap, MBBS, PhD, MRCP, PgDip, University of Texas MD Anderson Cancer Center, Houston, TX, outlines updates from the Phase I/II TRESR trail (NCT04497116) which assessed RP-3500, a ataxia telangiectasia and Rad3-related inhibitor (ATRi), in patients with DNA damage repair (DDR) loss-of-function mutant tumors. RP-3500 was well tolerated, with no grade 4 mechanism-based anemia events seen in the trial and grade 3 events occurring at a rate of 24%. Moreover, RP-3500 monotherapy resulted in durable clinical benefits in several tumor types and genomic alterations, with the overall clinical benefit rate being 43%. Importantly, in patients with ovarian cancer, 85% of whom were platinum-refractory and resistant, and 90% of whom had previously been treated with a PARP inhibitor, the overall response rate was 25%, the clinical benefit rate was 75%, and the median progression-free survival was 35 weeks. In patients with BRCA1 and BRCA2 mutated cancers who were previously treated with a PARP inhibitor, the clinical benefit was 48%. Many clinical trials investigating RP-3500 alone and in combination with other agents are currently being undertaken. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.

Disclosures

Employment: University of Texas MD Anderson Cancer Center, where I am Medical Director of the Institute for Applied Cancer Science, which has a commercial interest in DDR and other inhibitors (IACS30380/ART0380 was licensed to Artios)

Grant/Research support (to Institution): Acrivon, Artios, AstraZeneca, Bayer, Beigene, BioNTech, Blueprint, BMS, Clovis, Constellation, Cyteir, Eli Lilly, EMD Serono, Forbius, F-Star, GlaxoSmithKline, Genentech, Haihe, ImmuneSensor, Ionis, Ipsen, Jounce, Karyopharm, KSQ, Kyowa, Merck, Mirati, Novartis, Pfizer, Ribon Therapeutics, Regeneron, Repare, Rubius, Sanofi, Scholar Rock, Seattle Genetics, Tesaro, Vivace and Zenith.

Consultancies: AbbVie, AstraZeneca, Acrivon, Adagene, Almac, Aduro, Amphista, Artios, Athena, Atrin, Avoro, Axiom, Baptist Health Systems, Bayer, Beigene, Boxer, Bristol Myers Squibb, C4 Therapeutics, Calithera, Cancer Research UK, Clovis, Cybrexa, Diffusion, EMD Serono, F-Star, Genmab, Glenmark, GLG, Globe Life Sciences, GSK, Guidepoint, Idience, Ignyta, I-Mab, ImmuneSensor, Institut Gustave Roussy, Intellisphere, Jansen, Kyn, MEI pharma, Mereo, Merck, Natera, Nexys, Novocure, OHSU, OncoSec, Ono Pharma, Pegascy, PER, Pfizer, Piper-Sandler, Prolynx, Repare, resTORbio, Roche, Schrodinger, Theragnostics, Varian, Versant, Vibliome, Xinthera, Zai Labs and ZielBio